Ras oncogenes: split personalities

Cited by (1,000)

Items 101–200 of 1,000

1. A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition
   José L. McFaline‐Figueroa, Andrew J. Hill, Xiaojie Qiu, Dana L. Jackson, Jay Shendure, Cole Trapnell · 2019 · Nature Genetics
2. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy
   Saleha Anwar, Anas Shamsi, Taj Mohammad, Asimul Islam, Md. Imtaiyaz Hassan · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
3. Prognostic and Predictive Value in KRAS in Non–Small-Cell Lung Cancer: A Review
   Wood, Kevin, Hensing, Thomas, Malik, Raeva, Salgia, Ravi · 2016 · JAMA Oncology
4. Identification of pyrazolopyridazinones as PDEδ inhibitors
   Bjoern Papke, Sandip Murarka, Holger A. Vogel, Pablo Martín‐Gago, Marija Kovačević, Dina C. Truxius, Eyad K. Fansa, Shehab Ismail, Gunther Zimmermann, Kaatje Friederike Heinelt et al. · 2016 · Nature Communications
5. Single-Cell Transcriptome Analysis Reveals Dynamic Changes in lncRNA Expression during Reprogramming
   Daniel H. Kim, Georgi K. Marinov, Shirley Pepke, Zakary S. Singer, Peng He, Brian A. Williams, Gary P. Schroth, Michael B. Elowitz, Barbara J. Wold · 2015 · Cell stem cell
6. ERK signalling as a regulator of cell motility
   Susumu Tanimura, Kohsuke Takeda · 2017 · The Journal of Biochemistry
7. RNAi screens in mice identify physiological regulators of oncogenic growth
   Slobodan Beronja, Peter Janki, Evan Heller, Wen‐Hui Lien, Brice E. Keyes, Naoki Oshimori, Elaine V. Fuchs · 2013 · Nature
8. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
   Andrew M. Kidger, James Sipthorp, Simon J. Cook · 2018 · Pharmacology & Therapeutics
9. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer
   Diego Francesco Calvisi, Sara Ladu, Elizabeth A. Conner, Daekwan Seo, Jer‐Tsong Hsieh, Valentina M. Factor, Snorri S. Thorgeirsson · 2010 · Journal of Hepatology
10. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices
    Elizaveta S. Leshchiner, Andrey A. Parkhitko, Gregory H. Bird, James Luccarelli, Joseph A. Bellairs, Silvia Escudero, Kwadwo Opoku-Nsiah, Marina Godes, Norbert Perrimon, Loren D. Walensky · 2015 · Proceedings of the National Academy of Sciences
11. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders
    Gremer, Lothar, Merbitz-Zahradnik, Torsten, Dvorsky, Radovan, Cirstea, Ion C., Kratz, Christian Peter, Zenker, Martin, Wittinghofer, Alfred, Ahmadian, Mohammad Reza · 2011 · Human Mutation
12. Analysis of Binding Site Hot Spots on the Surface of Ras GTPase
    G. Buhrman, Casey O′Connor, Brandon S. Zerbe, Bradley M. Kearney, Raeanne L. Napoleon, Elizaveta A. Kovrigina, Sándor Vajda, Dima Kozakov, Evgenii L. Kovrigin, Carla Mattos · 2011 · Journal of Molecular Biology
13. H-Ras forms dimers on membrane surfaces via a protein–protein interface
    Wan‐Chen Lin, Lars Iversen, Hsiung‐Lin Tu, Christopher Rhodes, Sune M. Christensen, Jeffrey S. Iwig, Scott D. Hansen, William Y. C. Huang, Jay T. Groves · 2014 · Proceedings of the National Academy of Sciences
14. Molecular biomarkers for lung adenocarcinoma
    Olivier Calvayrac, Anne Pradines, Elvire Pons Tostivint, Julien Mazières, Nicolas Marie Guibert · 2017 · European Respiratory Journal
15. The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2
    Kovalski, Joanna R., Bhaduri, Aparna, Zehnder, Ashley M., Neela, Poornima H., Che, Yonglu, Wozniak, Glenn G., Khavari, Paul A. · 2019 · Molecular Cell
16. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR
    A Rojas, G Liu, Ilsa Coleman, Peter S. Nelson, Miqin Zhang, Rupesh Dash, Paul B. Fisher, Stephen R. Plymate, J D Wu · 2011 · Oncogene
17. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
    Weiss, Andreas, Lorthiois, Edwige, Barys, Louise, Beyer, Kim S., Bomio-Confaglia, Claudio, Burks, Heather, Chen, Xueying, Cui, Xiaoming, de Kanter, Ruben, Dharmarajan, Lekshmi et al. · 2022 · Cancer Discovery
18. Ras/MAPK signaling from endomembranes
    Fehrenbacher, Nicole, Bar-Sagi, Dafna, Philips, Mark · 2009 · Molecular Oncology
19. Inhibition of Ras Signaling by Blocking Ras–Effector Interactions with Cyclic Peptides
    Punit Upadhyaya, Ziqing Qian, Nicholas G. Selner, Sarah R. Clippinger, Zhengrong Wu, Roger Briesewitz, Dehua Pei · 2015 · Angewandte Chemie International Edition
20. RASMutations in Thyroid FNA Specimens Are Highly Predictive of Predominantly Low-Risk Follicular-Pattern Cancers
    Nikhil Gupta, Anil K. Dasyam, Sally E. Carty, Marina N. Nikiforova, N. Paul Ohori, Michaele J. Armstrong, Linwah Yip, Shane O. LeBeau, Kelly L. McCoy, Christopher Coyne et al. · 2013 · The Journal of Clinical Endocrinology & Metabolism
21. RAS mutations in human cancers: Roles in precision medicine
    Murugan, Avaniyapuram Kannan, Grieco, Michele, Tsuchida, Nobuo · 2019 · Seminars in Cancer Biology
22. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration
    Seungmin Shin, Dong-Ki Choi, Keun‐Ok Jung, Jeomil Bae, Ji‐Sun Kim, Seong-wook Park, Ki-Hoon Song, Yong‐Sung Kim · 2017 · Nature Communications
23. Human β-Cell Proliferation and Intracellular Signaling: Part 3
    Stewart, Andrew F., Hussain, Mehboob A., García-Ocaña, Adolfo, Vasavada, Rupangi C., Bhushan, Anil, Bernal-Mizrachi, Ernesto, Kulkarni, Rohit N. · 2015 · Diabetes
24. ER functions of oncogenes and tumor suppressors: Modulators of intracellular Ca2+ signaling
    Mart Bittremieux, Jan B. Parys, Paolo Pinton, Geert Bultynck · 2016 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
25. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth
    Yoshihisa Kobayashi, Tetsuya Mitsudomi, Yukinori Sakao, Yasushi Yatabe · 2014 · Annals of Oncology
26. ARF1 regulates the Rho/MLC pathway to control EGF-dependent breast cancer cell invasion
    Sabrina Schlienger, Shirley L. Campbell, Audrey Claing · 2013 · Molecular Biology of the Cell
27. Mutation-Induced Impacts on the Switch Transformations of the GDP- and GTP-Bound K-Ras: Insights from Multiple Replica Gaussian Accelerated Molecular Dynamics and Free Energy Analysis
    Jianzhong Chen, Shaolong Zhang, Wei Wang, Laixue Pang, Qinggang Zhang, Xinguo Liu · 2021 · Journal of Chemical Information and Modeling
28. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling
    Bas Ponsioen, Jasmin B. Post, Julian R. Buissant des Amorie, Dimitrios Laskaris, Ravian L. van Ineveld, Simone Kersten, Andrea Bertotti, Francesco Paolo Sassi, François Sipieter, Benjamin Cappe et al. · 2021 · Nature Cell Biology
29. Oncogenic K-Ras requires activation for enhanced activity
    Haojie Huang, Jarosław Daniluk, Y Liu, J Chu, Zhigang Li, Baoan Ji, Craig D. Logsdon · 2013 · Oncogene
30. The Chaperone TRAP1 As a Modulator of the Mitochondrial Adaptations in Cancer Cells
    Ionica Masgras, Carlos Sànchez‐Martìn, Giorgio Colombo, Andrea Rasola · 2017 · Frontiers in Oncology
31. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
    Zeng, Mei, Lu, Jia, Li, Lianbo, Feru, Frederic, Quan, Chunshan, Gero, Thomas W., Ficarro, Scott B., Xiong, Yuan, Ambrogio, Chiara, Paranal, Raymond M. et al. · 2017 · Cell Chemical Biology
32. Mst1 Promotes Cardiac Myocyte Apoptosis through Phosphorylation and Inhibition of Bcl-xL
    Dominic P. Del Re, Takahisa Matsuda, Peiyong Zhai, Yasuhiro Maejima, Mohit Raja Jain, Tong Liu, Hong Li, Chiao‐Po Hsu, Junichi Sadoshima · 2014 · Molecular Cell
33. Targeting metabolic reprogramming in KRAS-driven cancers
    Kenji Kawada, Kosuke Toda, Yoshiharu Sakai · 2017 · International Journal of Clinical Oncology
34. The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor
    Sara Koenig McLaughlin, Sarah Naomi Olsen, Benjamin T. Dake, Thomas De Raedt, Elgene Lim, Roderick Terry Bronson, Rameen Beroukhim, Kornélia Polyák, Myles A Brown, Charlotte Kuperwasser et al. · 2013 · Cancer Cell
35. KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer
    Petra Martin, Natasha B. Leighl, Ming‐Sound Tsao, Frances A. Shepherd · 2013 · Journal of Thoracic Oncology
36. Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells
    Yihua Wang, Hua Xiong, Dian Liu, Charlotte Nicole Hill, Ayse Ertay, Juanjuan Li, Yanmei Zou, Paul Miller, Eileen White, Julian Downward et al. · 2019 · Autophagy
37. Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
    Iris Z. Uras, Herwig Peter Moll, Emilio Casanova · 2020 · International Journal of Molecular Sciences
38. Mutant K-Ras Activation of the Proapoptotic MST2 Pathway Is Antagonized by Wild-Type K-Ras
    David Matallanas, David Romano, Fahd Al‐Mulla, Eric E. O’Neill, Waleed Al-Ali, Piero Crespo, Brendan J. Doyle, Colin Nixon, Owen James Sansom, Matthias Drosten et al. · 2011 · Molecular Cell
39. Comparative analysis of KRAS codon 12, 13, 18, 61 and 117 mutations using human MCF10A isogenic cell lines
    Britta Stolze, Stefanie Reinhart, Lars Bullinger, Stefan Fröhling, Claudia Scholl · 2015 · Scientific Reports
40. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
    Pascale Tomasini, Preet Walia, Catherine Labbé, Kevin Jao, Natasha B. Leighl · 2016 · The Oncologist
41. Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15
    Satoshi Inoue, Zhenyue Hao, Andrew Elia, David W. Cescon, Lily Zhou, Jennifer Silvester, Bryan E. Snow, Isaac S. Harris, Masato Sasaki, Wanda Y. Li et al. · 2013 · Genes & Development
42. Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas
    Mark L. McCleland, Adam S. Adler, Laura Deming, Ely Cosino, Leslie B. Lee, Elizabeth M. Blackwood, Margaret Solon, Janet Tao, Li Li, David S. Shames et al. · 2012 · Clinical Cancer Research
43. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
    Hilmar Quentmeier, Sonja Eberth, Julia Romani, Margarete Zaborski, Hans Günter Drexler · 2011 · Journal of Hematology & Oncology
44. The role of wild type RAS isoforms in cancer
    Zhou, Bingying, Der, Channing J., Cox, Adrienne D. · 2016 · Seminars in Cell & Developmental Biology
45. The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery
    Nicole F. Neel, Timothy D. Martin, Jeran K. Stratford, Tanya P. Zand, David J. Reiner, Channing J. Der · 2011 · Genes & Cancer
46. Ras-mediated activation of the TORC2–PKB pathway is critical for chemotaxis
    Huaqing Cai, Satarupa Das, Yoichiro Kamimura, Long Yu, Carole A. Parent, Peter N. Devreotes · 2010 · The Journal of Cell Biology
47. Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation
    Jon Winter, Malcolm Anderson, Kevin Blades, C. Brassington, Alexander L. Breeze, Christine M. Chresta, Kevin J. Embrey, Gary Fairley, Paul Faulder, M. Raymond V. Finlay et al. · 2015 · Journal of Medicinal Chemistry
48. Protein acyl thioesterases (Review)
    Ruth Zeidman, Caroline S. Jackson, Anthony I. Magee · 2009 · Molecular Membrane Biology
49. Ras acylation, compartmentalization and signaling nanoclusters (Review)
    Yoav I. Henis, John F. Hancock, Ian A. Prior · 2009 · Molecular Membrane Biology
50. Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells
    Barbara Sobotič, Matej Vizovišek, Robert Vidmar, Petra Van Damme, Vasilena Gocheva, Johanna A. Joyce, Kris Gevaert, Vito Türk, Boris Turk, Marko Fonovič · 2015 · Molecular & Cellular Proteomics
51. Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators
    Yuanxiang Wang, Christine E. Kaiser, Brendan Frett, Hongyu Li · 2013 · Journal of Medicinal Chemistry
52. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling
    Matteo Forloni, Shaillay Kumar Dogra, Yuying Dong, Darryl Conte, Jianhong Ou, Lihua Julie Zhu, April Deng, Meera Mahalingam, Michael R. Green, Narendra Wajapeyee · 2014 · eLife
53. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
    Li, Qing-Hai, Wang, Ying-Zhao, Tu, Jian, Liu, Chu-Wei, Yuan, Yu-Jie, Lin, Run, He, Wei-Ling, Cai, Shi-Rong, He, Yu-Long, Ye, Jin-Ning · 2020 · Gastroenterology Report
54. Regulation of RAS oncogenicity by acetylation
    Moon Hee Yang, Seth Nickerson, Eric T. Kim, Caroline Liot, Gaëlle Laurent, Robert Spang, Mark R. Philips, Yibing Shan, David Elliot Shaw, Dafna Bar‐Sagi et al. · 2012 · Proceedings of the National Academy of Sciences
55. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples
    Zhuang Zuo, Su S. Chen, Pranil Chandra, John M. Galbincea, Matthew P. Soape, Steven Doan, Bedia A. Barkoh, Hartmut Koeppen, Leonard Jeffrey Medeiros, Rajyalakshmi Luthra · 2009 · Modern Pathology
56. Ras oncogenes in oral cancer: The past 20 years
    Avaniyapuram Kannan Murugan, Arasambattu Kannan Munirajan, Nobuo Tsuchida · 2012 · Oral Oncology
57. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology
    Sakamoto, Kotaro, Kamada, Yusuke, Sameshima, Tomoya, Yaguchi, Masahiro, Niida, Ayumu, Sasaki, Shigekazu, Miwa, Masanori, Ohkubo, Shoichi, Sakamoto, Jun-ichi, Kamaura, Masahiro et al. · 2017 · Biochemical and Biophysical Research Communications
58. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
    Kyle Knickelbein, Lin Zhang · 2014 · Genes & Diseases
59. Emerging roles of allosteric modulators in the regulation of protein‐protein interactions (PPIs): A new paradigm for PPI drug discovery
    Ni, Duan, Lu, Shaoyong, Zhang, Jian · 2019 · Medicinal Research Reviews
60. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast
    Megan L. Troxell, Judith Levine, Carol Beadling, Andrea Warrick, Jennifer B. Dunlap, Ajia Presnell, Janice Patterson, Arielle Shukla, Neal Olson, Michael Charles Heinrich et al. · 2009 · Modern Pathology
61. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
    Abderrahim El Guerrab, Mahchid Bamdad, Fabrice Kwiatkowski, Yves‐Jean Bignon, Frederique Madeleine Penault-Llorca, Corinne Aubel · 2016 · Oncotarget
62. Anticancer effects of oleuropein
    Hesham Shamshoum, Filip Vlavcheski, Evangelia Tsiani · 2017 · BioFactors
63. The Role of PKC-MAPK Signalling Pathways in the Development of Hyperglycemia-Induced Cardiovascular Complications
    Fatin Farhana Jubaidi, Satirah Zainalabidin, Izatus Shima Taib, Zariyantey Abdul Hamid, Nur Najmi Mohamad Anuar, Juriyati Jalil, Nor Anizah Mohd Nor, Siti Balkis Budin · 2022 · International Journal of Molecular Sciences
64. Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1 H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C
    Shin, Youngsook, Jeong, Joon Won, Wurz, Ryan P., Achanta, Pragathi, Arvedson, Tara, Bartberger, Michael D., Campuzano, Iain D. G., Fucini, Ray, Hansen, Stig K., Ingersoll, John et al. · 2019 · ACS Medicinal Chemistry Letters
65. Development of siRNA Payloads to Target KRAS -Mutant Cancer
    Yuan, Tina L., Fellmann, Christof, Lee, Chih-Shia, Ritchie, Cayde D., Thapar, Vishal, Lee, Liam C., Hsu, Dennis J., Grace, Danielle, Carver, Joseph O., Zuber, Johannes et al. · 2014 · Cancer Discovery
66. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era
    Suja Pillai, Vinod Gopalan, Robert Anthony Smith, Alfred King-yin Lam · 2016 · Critical Reviews in Oncology/Hematology
67. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
    Bear, Adham S., Blanchard, Tatiana, Cesare, Joseph, Ford, Michael J., Richman, Lee P., Xu, Chong, Baroja, Miren L., McCuaig, Sarah, Costeas, Christina, Gabunia, Khatuna et al. · 2021 · Nature Communications
68. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
    Annette S. Little, Paul D. Smith, Simon J. Cook · 2012 · Oncogene
69. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development
    Asaf Shilo, Vered Ben-Hur, Polina Denichenko, Ilan Stein, Eli Pikarsky, Jens Rauch, Walter Kölch, Lars Zender, Rotem Karni · 2014 · RNA
70. EDAC: Epithelial defence against cancer--cell competition between normal and transformed epithelial cells in mammals
    Mihoko Kajita, Yasuyuki Fujita · 2015 · The Journal of Biochemistry
71. JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS G12C for the Treatment of Solid Tumors
    Lorthiois, Edwige, Gerspacher, Marc, Beyer, Kim S., Vaupel, Andrea, Leblanc, Catherine, Stringer, Rowan, Weiss, Andreas, Wilcken, Rainer, Guthy, Daniel A., Lingel, Andreas et al. · 2022 · Journal of Medicinal Chemistry
72. Ras signaling through RASSF proteins
    Howard Donninger, Marianne Schmidt, Jessica Mezzanotte-Sharpe, Thibaut Barnoud, Geoffrey J. Clark · 2016 · Seminars in Cell and Developmental Biology
73. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells
    Yihua Wang, Vu N. Ngo, Martyna Marani, Yandan Yang, George W. Wright, Louis M. Staudt, Julian Downward · 2010 · Oncogene
74. Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration
    Vipin Yadav, Mitchell F. Denning · 2010 · Molecular Carcinogenesis
75. The Many Faces of Rap1 GTPase
    Anna Jaśkiewicz, Beata Pająk, Arkadiusz Orzechowski · 2018 · International Journal of Molecular Sciences
76. Therapeutic targeting of RAS: New hope for drugging the “undruggable”
    Imran Khan, Joshua Matthew Rhett, John P. O’Bryan · 2019 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
77. Palmitoylation cycles and regulation of protein function (Review)
    Steinunn Bækkeskov, Jamil Kanaani · 2009 · Molecular Membrane Biology
78. Ras moves to stay in place
    Malte Schmick, Astrid Kraemer, Philippe I. H. Bastiaens · 2015 · Trends in Cell Biology
79. Ras and autophagy in cancer development and therapy
    Eran Schmukler, Yoel Kloog, Ronit Pinkas‐Kramarski · 2014 · Oncotarget
80. Characterization of KRAS Rearrangements in Metastatic Prostate Cancer
    Xiao-Song Wang, Sunita Shankar, Saravana Mohan Dhanasekaran, Bushra Ateeq, Atsuo T. Sasaki, Xiaojun Jing, Daniel Robinson, Qi Cao, John R. Prensner, Anastasia K. Yocum et al. · 2011 · Cancer Discovery
81. A Restricted Spectrum of Mutations in the SMAD4 Tumor-Suppressor Gene Underlies Myhre Syndrome
    Viviana Caputo, L Cianetti, Marcello Niceta, Claudio Carta, Andrea Ciolfi, Gianfranco Bocchinfuso, Eugenio Carrani, Maria Lisa Dentici, Elisa Biamino, Elga Fabia Belligni et al. · 2012 · The American Journal of Human Genetics
82. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF
    Cisowski, J, Sayin, V I, Liu, M, Karlsson, C, Bergo, M O · 2016 · Oncogene
83. Negative regulation of mTOR activation by diacylglycerol kinases
    Balachandra K. Gorentla, Edwin C. K. Wan, Xiao‐Ping Zhong · 2011 · Blood
84. Small G Proteins in the Cardiovascular System: Physiological and Pathological Aspects
    Gervaise Loirand, Vincent Sauzeau, Pierre Pacaud · 2013 · Physiological Reviews
85. Targeted Therapies for Lung Cancer
    Jill E. Larsen, Tina Cascone, David E. Gerber, John Victor Heymach, John Dorrance Minna · 2011 · The Cancer Journal
86. A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer
    Vasan, Neil, Boyer, Julie L., Herbst, Roy S. · 2014 · Clinical Cancer Research
87. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
    Jochen Gaedcke, Marian Grade, Klaus Jung, Markus Schirmer, Peter Jo, Christoph Obermeyer, Hendrik A. Wolff, Markus K. A. Herrmann, Tim Beißbarth, Heinz Becker et al. · 2009 · Radiotherapy and Oncology
88. OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination
    Maria Francesca Baietti, Michal Šimíček, Layka Abbasi Asbagh, Enrico Radaelli, Sam Lievens, Jonathan Crowther, Mikhail Yu. Steklov, Vasily N. Aushev, David Martínez‐García, Jan H. Tavernier et al. · 2016 · EMBO Molecular Medicine
89. Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function
    Rachael Baker, Steven M. Lewis, Atsuo T. Sasaki, Emily Wilkerson, Jason W. Locasale, Lewis C. Cantley, Brian A. Kuhlman, Henrik Gunnar Dohlman, Sharon L. Campbell · 2012 · Nature Structural & Molecular Biology
90. RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
    Ting Jin, Hugo Lavoie, Malha Sahmi, Maud David, Christine Hilt, Amy Hammell, Marc Therrien · 2017 · Nature Communications
91. Kinesins in MAPK cascade: How kinesin motors are involved in the MAPK pathway?
    Yajing Liang, Wan-Xi Yang · 2018 · Gene
92. SOS GEFs in health and disease
    Baltanás, Fernando C., Zarich, Natasha, Rojas-Cabañeros, Jose M., Santos, Eugenio · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
93. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer
    Wei‐Yu Chen, Shih-Yang Liu, Yung-Sheng Chang, Juan Juan Yin, Hsiu-Lien Yeh, Tarek H. Mouhieddine, Ola Hadadeh, Wassim G. Abou-Kheir, Yen‐Nien Liu · 2014 · Oncotarget
94. Aberrant phase separation and cancer
    Kenzui Taniue, Nobuyoshi Akimitsu · 2021 · FEBS Journal
95. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management
    Ioannis Manousaridis, Sofia Mavridou, Sergij Goerdt, M. Leverkus, Jochen Sven Utikal · 2012 · Journal of the European Academy of Dermatology and Venereology
96. A high level of liver-specific expression of oncogenic KrasV12 drives robust liver tumorigenesis in transgenic zebrafish
    Anh Tuan Nguyen, Alexander Emelyanov, Chor Hui Vivien Koh, Jan M. Spitsbergen, Siew Hong Lam, Sinnakaruppan Mathavan, Serguei Parinov, Zhiyuan Gong · 2011 · Disease Models & Mechanisms
97. Direct reprogramming by oncogenic Ras and Myc
    Irene Ischenko, Jizu Zhi, Ute Martha Moll, Alice Nemajerová, Oleksi Petrenko · 2013 · Proceedings of the National Academy of Sciences
98. Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation
    Severa Bunda, Pardeep Heir, Tharan Srikumar, Jonathan D. Cook, Kelly E. Burrell, Yoshihito Kano, Jeffrey E. Lee, Gelareh Mohammed Zadeh, Brian Raught, Michael Ohh · 2014 · Proceedings of the National Academy of Sciences
99. Frequency and Type of KRAS Mutations in Routine Diagnostic Analysis of Metastatic Colorectal Cancer
    Jens H. L. Neumann, Evelyn Zeindl‐Eberhart, Thomas Kirchner, Andreas Jung · 2009 · Zeitschrift für Gastroenterologie
100. Prohibitins Role in Cellular Survival Through Ras‐Raf‐MEK‐ERK Pathway
     Indrajit Chowdhury, Winston E. Thompson, Kelwyn Thomas · 2013 · Journal of Cellular Physiology